MAP2K7 and neoplasm: To test the predicted therapeutic efficacy of this combination in vivo, we again used our biclonal Mychigh/Myclow tumor model: High MycERT2 was activated in the Mychigh subpopulation, and 48 h later, mice were treated with either the COX2 inhibitor celecoxib or the MEK inhibitor PD0325901 alone, or with the 2 inhibitors combined.